TY  - JOUR
A1  - De Meyer, Sandra
A1  - Bojkova, Denisa
A1  - Cinatl, Jindrich
A1  - Damme, Ellen van
A1  - Buyck, Christophe
A1  - Loock, Marnix van
A1  - Woodfall, Brian
A1  - Ciesek, Sandra
T1  - Lack of antiviral activity of darunavir against SARS-CoV-2
T2  - International Journal of Infectious Diseases
N2  - Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Results: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM). Conclusions: Overall, the data do not support the use of DRV for the treatment of COVID-19.
KW  - Darunavir
KW  - SARS-CoV-2
KW  - COVID-19
KW  - In vitro
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54960
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-549606
SN  - 1878-3511
N1  - © 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
VL  - 97
SP  - 7
EP  - 10
PB  - Elsevier
CY  - Amsterdam [u.a.]
ER  -